Analysis of vitamin E metabolites including carboxychromanols and sulfated derivatives using LC/MS/MS

Qing Jiang, Tianlin Xu, Jianjie Huang, Amber S. Jannasch, Bruce Cooper, and Chao Yang

Department of Nutrition Science, and Metabolite Profiling Facility Bindley Bioscience Center, Purdue University, West Lafayette, IN 47907

Abstract  Tocopherols and tocotrienols are metabolized via hydroxylation and oxidation of their hydrophobic side chain to generate 13′-hydroxychromanols (13′-OHs) and various carboxychromanols, which can be further metabolized by conjugation including sulfation. Recent studies indicate that long-chain carboxychromanols, especially 13′-carboxychromanol (13′-COOH), appear to be more biactive than tocopherols in anti-inflammatory and anticancer actions. To understand the potential contribution of metabolites to vitamin E-mediated effects, an accurate assay is needed to evaluate bioavailability of these metabolites. Here we describe an LC/MS/MS assay for quantifying vitamin E metabolites using negative polarity ESI. This assay includes a reliable sample extraction procedure with efficacy of ≥ 89% and interday/intraday variation of 3–11% for major metabolites. To ensure accurate quantification, short-chain, long-chain, and sulfated carboxychromanols are included as external/ internal standards. Using this assay, we observed that sulfated carboxychromanols are the primary metabolites in the plasma of rodents fed with γ-tocopherol or δ-tocopherol. Although plasma levels of 13′-COOHs and 13′-OHs are low, high concentrations of these compounds are found in feces.

Our study demonstrates an LC/MS/MS assay for quantitation of sulfated and unconjugated vitamin E metabolites, and this assay will be useful for evaluating the role of these metabolites in vivo.—Jiang, Q., T. Xu, J. Huang, A. S. Jannasch, B. Cooper, and C. Yang. Analysis of vitamin E metabolites including carboxychromanols and sulfated derivatives using LC/MS/MS. J. Lipid Res. 2015. 56: 2217–2225.

Supplementary key words  tocopherol  •  tocotrienol  •  metabolism  •  liquid chromatography tandem mass spectrometry  •  sulfation

The vitamin E family comprises eight lipophilic antioxidants, α-, β-, γ- and δ-tocopherol (αT, βT, γT, and δT) and the corresponding tocotrienols (αTE, βTE, γTE, and δTE) (Fig. 1). Among the members of the vitamin E family, αT is the predominant form in tissues and is preferentially bound to a tocopherol transport protein that prevents αT from being extensively metabolized (1). In contrast, other vitamin E forms are largely metabolized in the liver via α-hydroxylation and oxidation to generate 13′-hydroxychromanol (13′-OH) and 13′-carboxychromanol (13′-COOH), the latter of which is subsequently metabolized via β-oxidation to various shorter-chain carboxychromanols including the terminal metabolite observed in urine, 3′-COOH [or 2-(β-carboxyethyl)-6-hydroxychroman (CEHC)] (Fig. 2) (1–3). In parallel with β-oxidation, long-chain carboxychromanols and CEHCs appear to be conjugated via sulfation to form conjugated carboxychromanols (Fig. 2) (4, 5). The terminal metabolite CEHCs and their conjugated forms are found in the urine (6–11). On the other hand, unconjugated short-, mid-, and long-chain carboxychromanols have recently been detected in feces after supplementation of γT or δT (12–14).

Although research on vitamin E has predominantly focused on tocopherols and tocotrienols, their metabolites have been shown to have biological activities that are stronger than or differ from the unmetabolized vitamins. For instance, γ-CEHC has been reported to have natriuretic activity in vitro and in animals (15). Recent studies including ours have demonstrated that long-chain carboxychromanols appear to have unique anti-inflammatory effects by inhibition of cyclooxygenases and 5-lipooxygenase and induced apoptosis in cancer cells (16–18). For these activities, long-chain carboxychromanols are much stronger than tocopherols or shorter-chain carboxychromanols. Despite these interesting findings of vitamin E metabolites,
their role in vitamin E-mediated beneficial effects remains unclear. One of the reasons is that there is limited information regarding the bioavailability of these metabolites in tissues. To this end, a reliable and accurate analytical method is needed to evaluate whether these metabolites can be generated at sufficient amounts in the body.

Although we have previously developed an HPLC-fluorescent assay for analyzing various vitamin E metabolites (4), this method is not suitable for simultaneously quantifying metabolites as a result of supplementation of a mixture of vitamin E forms. Previously published LC/MS assays are not ideal because they do not directly measure sulfated carboxychromanol and did not have suitable standards for extraction and quantification (19, 20). Furthermore, an assay using GC/MS, despite being highly sensitive, is not capable of directly detecting conjugated metabolites (9). In this study, we describe a sensitive LC/MS/MS assay that simultaneously analyzes hydroxychromans, carboxychromans, and sulfated metabolites. To ensure accurate quantification, our assay includes an improved sample processing procedure, and uses various carboxychromans and a sulfa-tated carboxychromanol as internal and external standards.

We then applied this assay to quantify bioavailability of vitamin E metabolites in plasma, urine, and fecal samples from rodents supplemented with vitamin E metabolites in plasma, urine, and fecal samples from rats. Furthermore, an assay using GC/MS, despite being highly sensitive, is not capable of directly detecting conjugated metabolites (9).

**MATERIALS AND METHODS**

**Materials**

αT (99%), γT (97%–99%), and δT (97%) were purchased from Sigma (St. Louis, MO). γ-CEHC (≥98%), α-CMHC, and (±)-α-T-5′-COOH (α-CMBHC) were from Cayman Chemicals (Ann Arbor, MI). δT-13′-COOH and δT-13′-COOH, which are metabolites from δT and δTE, respectively, were synthesized according to a published procedure (21). Tissue culture reagents were from Invitrogen (Rockville, MD). All other chemicals were purchased from Sigma.

**Cell culture**

The human alveolar epithelial A549 cells from American Type Culture Collection (Manassas, VA) were maintained routinely in RPMI-1640 with 10% FBS. For obtaining conditioned media, confluent cells (8–10 × 10⁵ cells per well in 6-well plates) were incubated with DMEM containing 1% FBS and γTE at 20 μM for 48 or 72 h (4). Media were collected, frozen immediately, and stored in −20°C until use. These conditioned media containing long-chain carboxychromans and sulfated metabolites (4) were used for optimizing LC/MS/MS conditions.

**Extraction of metabolites from plasma or cell culture media**

Plasma samples or cell culture media were extracted by a solvent mixture containing 6 vol of working methanol (containing 0.2 mg/ml ascorbic acid) and 12 vol of hexane via vigorous vortexing for 1 min. δT-13′-COOH (100 pmol) was added as an internal standard (IS). After centrifugation at 12,000 rpm for 2 min, the upper hexane layer was collected in a new tube with preadded butylated hydroxytoluene (BHT; 0.1 mg). The methanol layer (90–95%) was transferred into a clean tube, and the residual pellet was extracted one more time with 4 vol of working methanol. After vortexing and centrifugation, the combined methanol layers were dried under nitrogen. Both dried methanol- and hexane-extracted samples were resuspended in working methanol before being analyzed by HPLC or LC/MS/MS. During the extraction procedure, samples were protected from light.

Before LC/MS/MS analysis, α-CMBHC (1 or 5 μM) was added as an additional IS.

**Extraction of vitamin E metabolites from feces and urine**

Approximately 30 mg of fecal samples was homogenized in 2 ml of methanol with ascorbate (0.2 mg/ml). After centrifugation, 1.5 ml of methanol layer was dried and resuspended in 200 μl methanol, which was then diluted 10 times with addition of synthesized δT-13′-COOH (1 μM) as IS before being analyzed by LC/MS/MS. One hundred microliters of urine samples was added with δT-13′-COOH (1 μM) and extracted by 500 μl of working methanol (0.2 mg/ml ascorbic acid). The extraction was repeated one more time with 200 μl of working methanol. The combined methanol was dried under N₂. This procedure yielded >95% recovery of δT-13′-COOH.

**Analysis of vitamin E metabolites and vitamin E forms by HPLC with fluorescent detection**

As previously described (4), vitamin E metabolites, tocopherols, and tocotrienols were separated on a 150 × 4.6 mm, 5 μm Supelcosil™ LC-18-DB column using HPLC and detected by a Shimadzu RF-10AXL spectrofluorometric detector (Columbia, MD) with the excitation and emission wavelength at 292 nm and 327 nm, respectively. This method was used in experiments in studying the extraction efficacy and accuracy of metabolites and vitamin E forms.

**LC/MS/MS**

The LC/MS/MS analysis was done with an Agilent 1200 LC system coupled to an Agilent 6460 QQQ mass spectrometer equipped with a jet stream ESI source (Santa Clara, CA). The chromatography utilized an Atlantis dC18 column (2.1 × 150 mm, 3 μm) from Waters Corporation (Milford, MA). Buffer A consisted of acetonitrileethanol-water (165:135:700, v/v/v), and buffer B was acetonitrile-ethanol-water (539:441:20, v/v/v). The LC gradient was as follows: time 0 min, 0% B; time 1 min, 0%
housed in Purdue Life Science Animal Facility for a week for adaptation before experiments and then randomly grouped by body weight match. Rats were administered with $\gamma$-T or $\delta$-T at 100 mg/kg body weight by gavage using tocopherol-stripped corn oil (0.5 ml) as the vehicle (n = 3 in each group). Control animals received 0.5 ml of tocopherol-stripped corn oil. Six hours later, animals were euthanized, and plasma, liver, and other tissues were collected. In another study, rats were given $\gamma$-T at 50 mg/kg by gavage, and urine was collected for 7 h. The urine samples were then aliquoted and frozen at −80°C until use.

In the study of metabolite formation in response to $\gamma$-T- or $\delta$-T-supplemented diets, male Balb/c mice (5–6 weeks) were obtained from Harlan (Indianapolis, IN) and single-housed under controlled temperature with unrestricted access to diets and water. After a week of acclimatization, mice were randomly divided into control (AIN-93G diet) and $\gamma$-T- or $\delta$-T-supplemented (0.1% diet) group. These mice were subjected to induction of colon tumorigenesis by azoxymethane/dextran sodium sulfate (AOM/DSS) as previously described (12). When the study was terminated, mice were on supplemented diets for more than 150 days (12). During euthanasia, plasma and feces were collected.

**Statistical analysis**

In the study of extraction efficacy, ANOVA was used to calculate intraday and interday variances. Student’s $t$-test was used in...
the statistical analyses for comparison of controls with tocopherol-supplemented groups. All results are expressed as mean ± SD.

RESULTS

Optimization of sample processing procedure

In our previously published HPLC method, vitamin E metabolites were extracted into ethylacetate after sample solutions were acidified to pH <4. This protocol has been shown to effectively extract short- or medium-length carboxychromanols such as CEHC and 9′-COOH (4). However, extraction efficiency for 13′-COOHs by this procedure was not optimal, especially for plasma or serum samples (Q. Jiang, unpublished observations). Another weakness is that vitamin E forms and their metabolites need to be extracted separately by hexane/methanol, which requires additional samples. For these reasons, we decided to modify and optimize the extraction procedure aiming to effectively extract vitamin E forms and all the metabolites simultaneously from one (30–50 µl) biological sample.

To optimize and evaluate extraction efficacy, we used FBS spiked with vitamin E forms and metabolites including γT, δT, γ-CEHC, α-CEHC, α-CMBHC, δTE-13′-COOH, and δT-13′-COOH. The optimized extraction procedure included an extraction step with a solvent mixture containing 6 vol of methanol and 12 vol of hexane. After centrifugation, we collected both layers and performed an additional extraction of the pellet with 4 vol methanol (details in Materials and Methods). The hexane layer contains tocopherols and tocotrienols, and the combined methanol layer contains carboxychromanols and hydroxychromanols. This procedure yielded high extraction efficiency and accuracy, as indicated in Table 1 based on HPLC-fluorescent analyses.

Optimization of LC/MS/MS conditions

At the early stage of method development, we compared relative ionization efficacy of carboxychromanols among different MS ionization approaches including ESI and atmospheric pressure chemical ionization and photoionization interfaces. In these studies, we used δT-13′-COOH and γ-CEHC as the model compounds and found that ESI in the negative mode gave much stronger signals than other ionization methods.

We then optimized the ESI conditions by varying fragmentation transitions and collision energies for γ-CEHC, α-CEHC, 5′-COOH, δTE-13′-COOH, and δT-13′-COOH. To optimize ionization conditions of other metabolites including sulfated counterparts, we used conditioned media that contain sulfated carboxychromanols produced by incubation of A549 cells with γ-tocotrienol (4, 5). Typical fragmentations of carboxychromanols are shown in Fig. 3. Major fragmentations of various vitamin E metabolites were caused by loss of the side chain along with two carbons in the nonaromatic part of the chromanol (Fig. 3). An additional loss of -CH2 at the 4-position was observed for α-CMBHC. Sulfated metabolites were similarly fragmented with a signature loss of the sulfate group (Fig. 3).

To maximize signals, we chose the transition showing the highest intensity under varied collision energies for each analyte for quantifying carboxychromanols. The parameters for each carboxychromanols and vitamin E forms are summarized in Table 2.

It should be mentioned that besides sulfated metabolites, we attempted to directly detect glucuronidated carboxychromanols using full scan mode on a time-of-flight instrument or monitoring M+176 ions and fragments by product ion scanning, precursor loss scanning, and multiple reaction monitor. However, we did not observe significant formation of glucuronidated metabolites in the plasma of rats gavaged with tocopherols.

Quantification of sulfated carboxychromanols

Conjugated carboxychromanols have often been quantified after being converted to unconjugated counterparts by sulfatase/glucuronidase (22). However, this approach could not reveal the nature of conjugation and may be inappropriate when sample size is small. Further, our unpublished data indicate that many sulfatase or glucuronidases were not able to effectively deconjugate long-chain carboxychromanols such as sulfated-13′-carboxychromanol (13′S; unpublished observations). In order to directly quantify sulfated metabolites, we purified γTE-9′s from conditioned media from cells incubated with γTE (16) (Materials and Methods). The concentration of stock γTE-9′s was then determined by HPLC with UV-visible detection after being converted to γTE-9′-COOH with

|      | γ-CEHC | α-CEHC | α-CMBHC | δTE-13′ | δT-13′ | γT | δT |
|------|--------|--------|---------|---------|--------|----|----|
| Efficacy (%) | 97     | 89     | 96      | 98      | 95     | 107| 101|
| Intraday CV%  | 9      | 4      | 7       | 4       | 3      | 7  | 6  |
| Interday CV%  | 3      | 11     | 6       | 10      | 5      | 11 | 8  |

CV, coefficient of variation. Tocopherols and metabolites were spiked into FBS to yield γ-CEHC (2 µM), α-CEHC (10 µM), α-CMBHC (2 µM), δTE-13′-COOH (1 µM), δT-13′-COOH (0.4 µM), γT (0.4 µM), and δT (0.4 µM). One hundred microliters of spiked FBS was extracted by 600 µl working methanol (with 0.2 mg/ml ascorbic acid) and 1.2 ml hexane via vortexing vigorously for 1 min. After centrifugation for 2 min at 10,000 rpm, the upper hexane layer was transferred into a tube with preadded 10 µl BHT (10 mg/ml). The methanol layer was transferred into a clean tube, and the pellet was extracted with 400 µl working methanol for the second time. The two methanol extractions were combined and dried under N2. The dried methanol and hexane-extracted samples were resuspended in 100 µl working methanol before being analyzed by HPLC with fluorescent detection. Data are expressed as mean ± SD (based on ≥4 independent experiments).
assay for vitamin E metabolites can vary from time to time, it is necessary to quantify these compounds by internal and external standards that are analyzed along with biological samples. Specifically, in the subsequent analysis of biological samples, we used \( \gamma \)-H9254 T-13'-COOH and \( \delta \)-H9254 T-13'-COOH to quantify 13'-OHs and long-chain carboxychromanols, \( \beta \)-H9253 T-9'S for sulfated long-chain metabolites, and \( \gamma \)-CEHC or \( \alpha \)-CEHC for short-chain carboxychromanols. In these studies, \( \delta \)-H9254 T-13'-COOH and \( \alpha \)-CMBHC were used as IS and the rest as external standards.

We noticed that \( \delta \)-T-11'-S containing one (481.2 → 149) and two (479.2 → 149) double bonds have the same retention time (Table 2). Because these coeluted metabolites differ in one double bond, \(^{13}\)C isotopic correction will be necessary for proper quantification of these compounds (23).

Quantification of short- and long-chain metabolites in biological samples

We observed a broad range of linearity between LC/MS/MS response and analyte concentrations (from 10 nM to 5 \( \mu \)M) for short- and long-chain metabolites including \( \gamma \)-CEHC, \( \alpha \)-CEHC, \( \alpha \)-CMBHC, and 13'-COOHs. Under optimized ionization conditions, the detection limits for carboxychromanols were \(~0.1–0.4\) pmol on column with a signal-to-noise ratio of \( >8 \). To test ionization efficacy in extraction matrix, known amounts of \( \gamma \)-CEHC, \( \alpha \)-CMBHC, \( \gamma \)-TE-9'S, and \( \delta \)-T-13'-COOH were added to the reconstituted solution of FBS or plasma that were extracted by hexane/methanol with \( \delta \)-TE-13'-COOH as an IS. These samples were then analyzed under the optimized LC/MS conditions. We found that these compounds spiked in the plasma or FBS extracts showed similar ionization efficacy/intensity to those prepared in methanol, indicating that the extraction matrix does not have significant impact on ionization. These data, therefore, justify quantitation of metabolites using external standards combined with ISs. Because relative ionization efficacy among different carboxychromanols can vary from time to time, it is necessary to quantify these compounds by internal and external standards that are analyzed along with biological samples. Specifically, in the subsequent analysis of biological samples, we used \( \delta \)-T-13'-COOH and \( \delta \)-TE-13'-COOH to quantify 13'-OHs and long-chain carboxychromanols, \( \gamma \)-TE-9'S for sulfated long-chain metabolites, and \( \gamma \)-CEHC or \( \alpha \)-CEHC for short-chain carboxychromanols. In these studies, \( \delta \)-T-13'-COOH and \( \alpha \)-CMBHC were used as IS and the rest as external standards.

We noticed that \( \gamma \)-TE-derived long-chain metabolites bearing different numbers of double bonds were coeluted under the current LC conditions. For instance, \( \gamma \)-TE-11'S containing one (481.2 → 149) and two (479.2 → 149) double bonds have the same retention time (Table 2). Because these coeluted metabolites differ in one double bond, \(^{13}\)C isotopic correction will be necessary for proper quantification of these compounds (23).

Vitamin E metabolites detected in the plasma and feces of mice fed \( \gamma \)-T- or \( \delta \)-T-supplemented diets

Using the established LC/MS/MS assay, we found that mice fed a diet supplemented with \( \gamma \)-T or \( \delta \)-T had low but detectable amounts of CEHC (3'-COOH) and sulfated long-chain carboxychromanols as well as 13'-COOH in the plasma, whereas none of these metabolites were detectable.

**Fig. 3.** LC/MS/MS fragmentation of vitamin E metabolites.
in mice fed the control AIN93G diet (Table 3). Interestingly, in contrast to low concentrations of metabolites in the plasma, we found relatively high levels of unconjugated short-, mid-, and long-carboxychromanols in feces. Among fecal excretion metabolites, 13'-COOH and 13'-OH were the predominant vitamin E metabolites (Table 4).

### TABLE 3. MS conditions for vitamin E metabolites

| Compound Name | Precursor Ion | Product Ion | Retention Time (min) | Fragmentor | Collision Energy |
|---------------|---------------|-------------|----------------------|------------|-----------------|
| α-CHEC (α-3'-COOH) | 277.2 | 233 | 12.4 | 120 | 10 |
| α-5'-COOH | 319.2 | 150 | 18.4 | 180 | 20 |
| α-7'-COOH | 347.2 | 163 | — | 180 | 20 |
| α-9'-COOH | 389.3 | 163 | — | 120 | 35 |
| α-11'-COOH | 417.3 | 163 | — | 120 | 35 |
| α-13'-COOH | 450.4 | 163 | 30.1 | 120 | 35 |
| α-15'-OH | 445.4 | 163 | 32.5 | 120 | 35 |
| α-Tocopherol | 429.4 | 163 | 36.8 | 120 | 35 |
| δ-CHEC (δ-3'-COOH) | 249.1 | 205 | 9.8 | 120 | 10 |
| δ-SO4-CHEC | 329.1 | 135 | 5.3 | 120 | 45 |
| δ-5'-COOH | 291.2 | 135 | — | 180 | 30 |
| δ-7'-COOH | 319.2 | 135 | 19.1 | 180 | 20 |
| δ-9'-COOH | 361.3 | 135 | — | 120 | 35 |
| δ-11'-COOH | 389.3 | 135 | 27.0 | 120 | 35 |
| δ-13'-OH | 417.3 | 135 | 31.3 | 120 | 35 |
| δ-15'-COOH | 431.3 | 135 | 30.3 | 120 | 35 |
| δ-SO4-9'-COOH | 441.2 | 135 | 29.6 | 120 | 45 |
| δ-SO4-11'-COOH | 469.2 | 135 | 23.2 | 120 | 45 |
| δ-SO4-13'-COOH | 511.3 | 135 | 26.7 | 120 | 45 |
| δ-Tocopherol | 401.4 | 135 | 34.6 | 120 | 35 |
| δ-TE-5'-COOH (one double bond) | 289.2 | 135 | — | 120 | 35 |
| δ-TE-7'-COOH (one double bond) | 317.2 | 135 | — | 120 | 35 |
| δ-TE-9'-COOH (one double bond) | 359.2 | 135 | — | 120 | 35 |
| δ-TE-9'-COOH (two double bonds) | 357.2 | 135 | — | 120 | 35 |
| δ-TE-11'-COOH (two double bonds) | 385.3 | 135 | — | 120 | 35 |
| δ-TE-11'-COOH (one double bond) | 387.3 | 135 | — | 120 | 35 |
| δ-TE-13'-OH | 411.3 | 135 | — | 120 | 35 |
| δ-TE-15'-COOH (three double bonds) | 425.3 | 135 | 27.7 | 120 | 30 |
| δ-TE-15'-COOH (two double bonds) | 427.3 | 135 | — | 120 | 30 |
| δ-TE-SO4-9'-COOH (one double bond) | 439.2 | 135 | — | 120 | 45 |
| δ-TE-SO4-9'-COOH (two double bonds) | 437.2 | 135 | — | 120 | 45 |
| δ-TE-SO4-11'-COOH (two double bonds) | 465.2 | 135 | — | 120 | 45 |
| δ-TE-SO4-11'-COOH (one double bond) | 467.3 | 135 | — | 120 | 45 |
| δ-TE-SO4-13'-COOH (three double bonds) | 505.2 | 135 | — | 120 | 45 |
| δ-TE-SO4-13'-COOH (two double bonds) | 507.3 | 135 | — | 120 | 45 |
| δ-Tocotrienol | 395.3 | 135 | — | 120 | 35 |
| γ-CHEC (γ-3'-COOH) | 263.1 | 219 | 10.9 | 120 | 25 |
| γ-5'-COOH | 305.2 | 149 | 18.3 | 180 | 20 |
| γ-7'-COOH | 333.2 | 149 | — | 180 | 20 |
| γ-9'-COOH | 373.3 | 149 | 25.2 | 120 | 40 |
| γ-11'-COOH | 403.3 | 149 | 27.6 | 120 | 40 |
| γ-13'-OH | 431.4 | 149 | 31.2 | 120 | 40 |
| γ-13'-COOH | 445.3 | 149 | 30.6 | 120 | 40 |
| γ-SO4-CHEC | 343.1 | 149 | 6.2 | 120 | 30 |
| γ-SO4-9'-COOH | 455.2 | 149 | 20.7 | 120 | 45 |
| γ-SO4-11'-COOH | 483.3 | 149 | 23.2 | 120 | 45 |
| γ-SO4-13'-COOH | 525.3 | 149 | 26.7 | 120 | 45 |
| γ-Tocopherol | 415.4 | 149 | 36.1 | 120 | 40 |
| γ-TE-5'-COOH | 303.2 | 149 | — | 120 | 25 |
| γ-TE-7'-COOH (one double bond) | 331.2 | 149 | — | 120 | 25 |
| γ-TE-9'-COOH (two double bonds) | 371.2 | 149 | — | 120 | 25 |
| γ-TE-9'-COOH (one double bond) | 373.3 | 149 | 23.7 | 120 | 25 |
| γ-TE-11'-COOH (two double bonds) | 399.3 | 149 | 25.0 | 120 | 25 |
| γ-TE-11'-COOH (one double bond) | 401.3 | 149 | — | 120 | 25 |
| γ-TE-13'-OH (three double bonds) | 425.3 | 149 | 28.9 | 120 | 35 |
| γ-TE-13'-COOH (three double bonds) | 439.3 | 149 | 27.8 | 120 | 35 |
| γ-TE-13'-COOH (two double bonds) | 441.3 | 149 | 27.8 | 120 | 35 |
| γ-TE-SO4-9'-COOH (two double bonds) | 451.2 | 149 | — | 120 | 45 |
| γ-TE-SO4-9'-COOH (one double bond) | 453.2 | 149 | 19.2 | 120 | 45 |
| γ-TE-SO4-11'-COOH (two double bonds) | 479.2 | 149 | 20.6 | 120 | 45 |
| γ-TE-SO4-11'-COOH (one double bond) | 481.2 | 149 | 20.6 | 120 | 45 |
| γ-TE-SO4-13'-COOH (three double bonds) | 519.3 | 149 | 23.7 | 120 | 45 |
| γ-TE-SO4-13'-COOH (two double bonds) | 521.3 | 149 | 23.7 | 120 | 45 |
| γ-Tocotrienol | 409.3 | 149 | 33.1 | 120 | 35 |

All the parameters are set using ESI negative mode. The transitions with retention time have been confirmed by the experimental data.
Metabolites detected in the plasma and urine after a single gavage of \( \gamma T \) and \( \delta T \)

To evaluate the bioavailability of metabolites as a result of a high supplement dose of tocopherols, we gave rats a single gavage of \( \gamma T \) or \( \delta T \) at 100 mg/kg body weight and collected plasma samples 6 h later. We found that sulfated CEHCs (SO\( _4 \)-CEHC), 9'S, and 11'S were among the major metabolites in the plasma of tocopherol-supplemented rats (Table 5). Unlike analyses by HPLC with fluorescent detection (4, 5), the LC/MS/MS method allowed direct measurement of sulfated CEHCs. Compared with feeding on tocopherol-supplemented diet, oral gavage resulted in much elevated conjugated carboxychromanols in the rats’ plasma at the time of sample collection (cf. Tables 3 and 5).

In a separate animal study, we collected urine samples within 7 h after rats were gavaged with \( \gamma T \) at 50 mg/kg or corn oil (controls). We observed high excretion of sulfated \( \gamma \)-CEHC even in control rats (i.e., 16.4 ± 2.4 \( \mu \)mol/g) but could not detect \( \gamma \)-CEHC. Supplementation of \( \gamma T \) led to increase of sulfated \( \gamma \)-CEHC and unconjugated form to 78.59 ± 35.9 and 0.014 ± 0.003 \( \mu \)mol/g, respectively.

**DISCUSSION**

We have developed a highly sensitive and specific LC/MS/MS assay for simultaneously analyzing hydroxychromanols, carboxychromanols, and sulfated vitamin E metabolites. Our method is strengthened by optimized ionization of major metabolites and an improved extraction procedure that results in high sensitivity and excellent reproducibility. We have used multiple carboxychromanols as external standards and ISs to ensure accurate quantification. In addition, our method has a 9’S as a standard, which allows direct quantification of sulfated metabolites without the need for enzyme digestion. As a result, our study, for the first time, documented the level of sulfated CEHCs in the

| Metabolites (\( \mu \)M) | Control | \( \gamma T \) diet (0.1%) | \( \delta T \) diet (0.1%) |
|-------------------------|---------|--------------------------|--------------------------|
| \( \alpha \)-CEHC        | 0.034 ± 0.11 | 0.026 ± 0.01 | 0.029 ± 0.01 |
| \( \gamma \)-CEHC        | Low     | 0.085 ± 0.031*           | 0.012 ± 0.004 |
| 9'S                     | Low     | \( \gamma T \)-9'S: 0.04 ± 0.011* | \( \delta T \)-9'S: 0.032 ± 0.006* |
| 11'S                    | Low     | \( \gamma T \)-11'S: 0.023 ± 0.016* | \( \delta T \)-11'S: 0.054 ± 0.01* |
| 13'S                    | Low     | \( \gamma T \)-13'S: 0.0085 ± 0.0042 | \( \delta T \)-13'S: 0.032 ± 0.007* |
| \( \delta \)-CEHC        | Low     | \( \gamma T \)-13': 0.021 ± 0.0021* | \( \delta T \)-13': 0.01 ± 0.005 |

*P < 0.05: difference between control and supplemented diets.

**TABLE 4. Metabolites detected in fecal samples from mice fed diet supplemented with \( \gamma T \) or \( \delta T \) (0.1% diet)**

| Metabolites (\( \mu \)mol/g) | Control | \( \gamma T \) diet (0.1%) | \( \delta T \) diet (0.1%) |
|-----------------------------|---------|--------------------------|--------------------------|
| \( \gamma \)-CEHC            | Low     | 0.082 ± 0.036*           | Low                      |
| \( \delta \)-COOH            | Low     | \( \gamma T \)-5': 0.04 ± 0.011* | \( \delta T \)-5': 0.029 ± 0.03* |
| \( \delta \)-COOH            | Low     | \( \gamma T \)-7': 0.024 ± 0.017* | \( \delta T \)-7': 0.012 ± 0.003* |
| 9'-COOH                     | Low     | \( \gamma T \)-9': 0.094 ± 0.047* | \( \delta T \)-9': 0.031 ± 0.014* |
| 11'-COOH                    | Low     | \( \gamma T \)-11': 0.15 ± 0.05* | \( \delta T \)-11': 0.12 ± 0.06* |
| \( \alpha \)-13'-COOH        | 0.015 ± 0.004 | 0.029 ± 0.01 | 0.030 ± 0.01 |
| \( \gamma T \)-13'-COOH     | 0.03 ± 0.023 | 1.04 ± 0.24** | 0.18 ± 0.06** |
| \( \delta T \)-13'-COOH     | 0.015 ± 0.01 | 0.078 ± 0.06 | 0.96 ± 0.47** |
| \( \alpha \)-13'-OH          | 0.013 ± 0.01 | 0.022 ± 0.01 | 0.025 ± 0.01 |
| \( \gamma T \)-13'-OH       | 0.03 ± 0.021 | 0.34 ± 0.08** | 0.064 ± 0.03 |
| \( \delta T \)-13'-OH       | 0.025 ± 0.01 | 0.043 ± 0.02 | 0.67 ± 0.33** |

*Fecal samples were obtained from the same animal study described in Table 3. “Low” indicates below or at detection limit. Data are expressed as mean ± SD (n = 3–5 per group). *P < 0.05, **P < 0.01: difference between control and supplemented diets.

**TABLE 3. Metabolites in the plasma of mice fed \( \gamma T \)- or \( \delta T \)-supplemented diet**

| Metabolites (\( \mu \)M) | Control | \( \gamma T \) diet (0.1%) | \( \delta T \) diet (0.1%) |
|-------------------------|---------|--------------------------|--------------------------|
| \( \alpha \)-CEHC        | 0.034 ± 0.11 | 0.026 ± 0.01 | 0.029 ± 0.01 |
| \( \gamma \)-CEHC        | Low     | 0.085 ± 0.031*           | 0.012 ± 0.004 |
| 9'S                     | Low     | \( \gamma T \)-9'S: 0.04 ± 0.011* | \( \delta T \)-9'S: 0.032 ± 0.006* |
| 11'S                    | Low     | \( \gamma T \)-11'S: 0.032 ± 0.016* | \( \delta T \)-11'S: 0.045 ± 0.01* |
| 13'S                    | Low     | \( \gamma T \)-13'S: 0.0085 ± 0.0042 | \( \delta T \)-13'S: 0.032 ± 0.007* |
| \( \delta \)-CEHC        | Low     | \( \gamma T \)-13': 0.021 ± 0.0021* | \( \delta T \)-13': 0.01 ± 0.005 |

*P < 0.05: difference between control and supplemented diets.

Balb/c mice were fed AIN93G control diet or \( \gamma T \)- or \( \delta T \)-supplemented diet (0.1% w/w) for 3 months, and these mice were subjected to AOM/DSS treatment (see Materials and Methods for details). Plasma samples were collected and extracted for LC/MS/MS analysis. “Low” indicates below or at the detection limit. Data are expressed as mean ± SD (n = 3–5 per group).

More detailed tables and figures are provided in the document.
any significant amount of these metabolites in the plasma of rats gavaged with \( \gamma \)T. It remains to be determined whether glucuronidated carboxychromanols can be seen in other tissue or human samples.

Using the developed LC/MS/MS assay, we found some interesting aspects of vitamin E metabolite formation in response to supplementation of \( \gamma \)T or \( \delta \)T. First, administration of \( \gamma \)T or \( \delta \)T via a single gavage appeared to achieve much higher plasma concentrations of sulfated carboxychromanols than the steady concentrations achieved via chronic feeding with tocopherol-supplemented diets. This observation can be explained by the fact that animals consume a much smaller amount of \( \gamma \)T or \( \delta \)T from supplemented diet at any given time than a single gavage by which tocopherols were given as a large boost. That relatively high plasma levels of sulfated metabolites were detected after gavage indicates that sulfation of long-chain or intermediate carboxychromanols takes place in parallel with \( \beta \)-oxidation when a relatively large quantity of tocopherols is consumed. Second, large amounts of unconjugated metabolites, especially \( 13' \)-COOH and \( 13' \)-OH, which are very low in the plasma, are detected in feces. This observation is consistent with previous reports (12–14). The high level of carboxychromanols in feces suggests that most long-chain metabolites are not transported to the circulation after being generated in the liver, but rather are excreted via the bile. It has recently been estimated that up to 70% of vitamin E metabolites may be excreted to feces (13, 14). Alternatively, it is also possible that high levels of these metabolites in feces are produced by gut flora, an intriguing possibility warranting further investigation. Regardless, our current results together with previous reports confirm that \( 13' \)-COOH and \( 13' \)-OH are the major fecal excretion metabolites of vitamin E. In addition, although conjugated CEHCs have been reported in the urine (6–11), here we quantified sulfated \( \gamma \)CEHC. Interestingly, there are substantial amounts of \( SO_2 \gamma \)-CEHC even in the urine of control rats that were fed standard chow containing \( \approx 9 \) mg/kg of \( \gamma \)T.

It has been demonstrated that specific vitamin E metabolites are more bioactive or have different activities compared with unmetabolized vitamins. \( \gamma \)CEHC, but not tocopherols, has natriuretic activity (15) and is thought to be responsible for enhanced sodium excretion in response to supplementation of \( \gamma \)TE in rodents (24). We have demonstrated that \( 13' \)-COOHs are competitive inhibitors of cyclooxygenases, whereas none of the tocopherols or sulfated long-chain metabolites directly inhibit the cyclooxygenase activity (16). \( 13' \)-COOH derived from \( \delta \)T inhibits 5-lipoxygenase activity and leukotriene formation in stimulated neutrophils. On the other hand, tocopherols have no effect on 5-lipoxygenase activity, and their suppression of leukotriene in white blood cells varies with specific stimuli (17). In addition, \( 13' \)-COOHs induce apoptosis in liver hepatoma HpG2 cells more effectively than tocopherols (18). \( 13' \)-OH and \( 13' \)-COOH derived from \( \alpha \)T are found to have antiatherogenic activities (25). Given these bioactivities of long-chain metabolites, it is reasonable to assume that these compounds may play a role in vitamin E-mediated beneficial effects in vivo (1), which warrants further investigation.

In summary, we have described an LC/MS/MS assay that simultaneously quantifies hydroxychromanols, carboxychromanols, and sulfated vitamin E metabolites. This method should be useful for further evaluation of pharmacokinetics of vitamin E metabolite formation and their bioavailability in tissues and excretion, as well as for investigation of potential contributions of metabolites to vitamin E-mediated beneficial effects in animals and humans. 

### References

1. Jiang, Q. 2014. Natural forms of vitamin E: metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. *Free Radic. Biol. Med.* 72: 76–90.
2. Büringer, M., P. Pfluger, D. Kluth, N. Landes, and R. Biegelsen-Flohe. 2002. Identities and differences in the metabolism of tocotrienols and tocopherols in HepG2 cells. *J. Nutr.* 132: 3113–3118.
3. Sonntag, T. J., and R. S. Parker. 2002. Cytochrome P450 omega-hydroxylase pathway of tocopherol catabolism. Novel mechanism of regulation of vitamin E status. *J. Biol. Chem.* 277: 25290–25296.
4. Jiang, Q., H. Freiser, K. V. Wood, and X. Yin. 2007. Identification and quantitation of novel vitamin E metabolites, sulfated long-chain carboxychromanols.
chain carboxychromanols, in human A549 cells and in rats. *J. Lipid Res.* **48**: 1221–1230.

5. Freiser, H., and Q. Jiang. 2009. Gamma-tocotrienol and gamma-tocopherol are primarily metabolized to conjugated 2-(beta-carboxyethyl)-6-hydroxy-2,7,8-trimethylchroman and sulfated long-chain carboxychromanols in rats. *J. Nutr.* **139**: 884–889.

6. Chiku, S., K. Hamamura, and T. Nakamura. 1984. Novel urinary metabolite of d-delta-tocopherol in rats. *J. Lipid Res.* **25**: 40–48.

7. Schultz, M., L. Leist, M. Petrzika, B. Gassmann, and R. Brigelius-Flohe. 1995. Novel urinary metabolite of alpha-tocopherol, 2,5,7,8-tetramethyl-2-(2′-carboxyethyl)-6-hydroxychroman, as an indicator of an adequate vitamin E supply? *Am. J. Clin. Nutr.* **62**: 15275–15348.

8. Traber, M. G., A. Elsner, and R. Brigelius-Flohe. 1998. Synthetic as compared with natural vitamin E is preferentially excreted as alpha-CEHC in human urine: studies using deuterated alpha-tocopheryl acetates. *FEBS Lett.* **437**: 145–148.

9. Swanson, J. E., R. N. Ben, G. W. Burton, and R. S. Parker. 1999. Urinary excretion of 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxychroman is a major route of elimination of gamma-CEHC in humans. *J. Lipid Res.* **40**: 665–671.

10. Stahl, W., P. Graf, R. Brigelius-Flohe, W. Wechter, and H. Sies. 1999. Quantification of the alpha- and gamma-tocopherol metabolites 2,5,7,8-tetramethyl-2-(2′-carboxyethyl)-6-hydroxychroman and 2,7,8-trimethyl-2-(2′-carboxyethyl)-6-hydroxychroman in human serum. *Anal. Biochem.* **275**: 254–259.

11. Pope, S. A., G. E. Burtin, P. T. Clayton, D. J. Madge, and D. P. Muller. 2002. Synthesis and analysis of conjugates of the major vitamin E metabolite, alpha-CEHC. *Free Radic. Biol. Med.* **33**: 807–817.

12. Jiang, Q., Z. Jiang, Y. J. Hall, Y. Jang, P. W. Snyder, C. Bain, J. Huang, A. Jannasch, B. Cooper, Y. Wang, et al. 2013. Gamma-tocopherol attenuates moderate but not severe colitis and suppresses moderate colitis-promoted colon tumorigenesis in mice. *Free Radic. Biol. Med.* **55**: 1069–1077.

13. Bardowell, S. A., X. Ding, and R. S. Parker. 2012. Disruption of P450-mediated vitamin E hydroxylase activities alters vitamin E status in tocopherol supplemented mice and reveals extra-hepatic vitamin E metabolism. *J. Lipid Res.* **53**: 2067–2076.

14. Bardowell, S. A., F. Duan, D. Manor, J. E. Swanson, and R. S. Parker. 2012. Disruption of mouse cytochrome p450 4f14 (Cyp4f14 gene) causes severe perturbations in vitamin E metabolism. *J. Biol. Chem.* **287**: 26077–26086.

15. Wechter, W. J., D. Kantoci, E. D. Murray, Jr., D. C. D’Amico, M. E. Jung, and W. H. Wang. 1996. A new endogenous natriuretic factor: LLU-α. *Proc. Natl. Acad. Sci. USA.* **93**: 6002–6007.

16. Jiang, Q., X. Yin, M. A. Lill, M. L. Danielson, H. Freiser, and J. Huang. 2008. Long-chain carboxychromanols, metabolites of vitamin E, are potent inhibitors of cyclooxygenases. *Proc. Natl. Acad. Sci. USA.* **105**: 29464–29469.

17. Jiang, Z., X. Yin, and Q. Jiang. 2011. Natural forms of vitamin E and 13′-carboxychromanol, a long-chain vitamin E metabolite, inhibit leukotriene generation from stimulated neutrophils by blocking calcium influx and suppressing 5-lipoxygenase activity, respectively. *J. Immunol.* **186**: 1173–1179.

18. Birringer, M., D. Lington, S. Vertuani, S. Manfredini, D. Scharlau, M. Glei, and M. Ristow. 2010. Proapoptotic effects of long-chain vitamin E metabolites in HepG2 cells are mediated by oxidative stress. *Free Radic. Biol. Med.* **49**: 1315–1322.

19. Leonard, S. W., E. Gumpricht, M. W. Devereaux, R. J. Sokol, and M. G. Traber. 2005. Quantitation of rat liver vitamin E metabolites by LC-MS during high-dose vitamin E administration. *J. Lipid Res.* **46**: 1068–1075.

20. Zhao, Y. M. J. Lee, C. Cheung, J. H. Ju, Y. K. Chen, B. Liu, L. Q. Hu, and C. S. Yang. 2010. Analysis of multiple metabolites of tocopherols and tocotrienols in mice and humans. *J. Agric. Food Chem.* **58**: 4841–4852.

21. Maloney, D. J., and S. M. Hecht. 2005. A stereocontrolled synthesis of delta-trans-tocotrienolic acid. *Org. Lett.* **7**: 4297–4300.

22. Freiser, H., and Q. Jiang. 2009. Optimization of the enzymatic hydrolysis and analysis of plasma conjugated gamma-CEHC and sulfated long-chain carboxychromanols, metabolites of vitamin E. *Anal. Biochem.* **388**: 260–265.

23. Yang, K., and X. Han. 2011. Accurate quantification of lipid species by electrospray ionization mass spectrometry—Meet a key challenge in lipidomics. *Metabolites.* **1**: 21–40.

24. Saito, H., C. Kiyose, H. Yoshimura, T. Ueda, K. Kondo, and O. Igarashi. 2003. Gamma-tocotrienol, a vitamin E homolog, is a natriuretic hormone precursor. *J. Lipid Res.* **44**: 1530–1535.

25. Wållert, M., L. Schmida, A. Koerbeler, V. Krauth, M. Glei, F. Galli, O. Werz, M. Birringer, and S. Lorkowski. 2015. Alpha-Tocopherol long-chain metabolite alpha-13′-COOH affects the inflammatory response of lipopolysaccharide-activated murine RAW264.7 macrophages. *Mol. Nutr. Food Res.* **59**: 1524–1534.